New: discover the R&D tax incentives your business may be eligible for.Join the Waitlist
GrantsMAXGrantsMAXbeta
All posts
Guide

The R&D Tax Incentive for biotech and life sciences

A step-by-step guide for Australian biotech and life sciences companies exploring the R&D Tax Incentive, eligibility for lab and trial work, substantiation

TGThe GrantsMAX Team
12 minutes read

Prerequisites

Before you map biotech R&D activities to the tax incentive, assemble a few essentials. You will need:

  • Access to your business’s accounting data, typically through cloud accounting software like Xero, MYOB, or QuickBooks. The R&D Tax Incentive requires a detailed cost breakdown, and feeding clean data into the claim process saves weeks of manual reconciliation. GrantsMAX connects to your accounting data to draft that structure automatically, but you can also pull the figures manually.
  • A clear picture of your R&D projects, the experiments, assays, formulation trials, preclinical work, or pilot batches that involved a systematic progression from hypothesis to outcome. This will feed the required AusIndustry registration.
  • A registered tax agent or accountant who understands the R&D Tax Incentive. The ATO and the Tax Practitioners Board insist that only a registered agent can prepare and lodge a company tax return that includes an R&D claim. GrantsMAX prepares an evidence-backed pack for your accountant to review and lodge, but the lodgment step itself is the accountant’s domain.
  • Awareness that this article is general information, not tax, financial, or legal advice. Eligibility depends on your specific facts. Always confirm your position with a registered tax agent and refer to official sources: the ATO (ato.gov.au), AusIndustry and the Department of Industry, Science and Resources (business.gov.au), and, for export-related R&D, Austrade.

With those prerequisites in place, you can work through the steps below.

Step 1: Map your biotech R&D activities to core and supporting R&D categories

The R&D Tax Incentive defines two tiers of activity: core R&D activities and supporting R&D activities. Biotech and life sciences companies frequently engage in both.

Core R&D activities

Core R&D activities are experimental activities whose outcome cannot be known or determined in advance on the basis of current knowledge, and that are conducted for the purpose of generating new knowledge. In biotech, these often include:

  • Wet-lab experiments to test a novel gene-silencing construct.
  • Formulation trials for a new sustained-release drug delivery system.
  • Microbiological challenge studies to validate a novel disinfectant or coating.
  • Early-stage in vitro assays that probe an entirely new mechanism of action.
  • Computational biology workflows where the outcome is not predictable from existing algorithms.

Crucially, the activity must be conducted in Australia or, if conducted overseas, meet the strict “overseas findings” rules described later. The Australian Government, through AusIndustry, expects that you can articulate the hypothesis that was tested and why the result could not have been predicted beforehand.

Supporting R&D activities

Supporting R&D activities are activities directly related to core R&D activities. In biotech, these regularly include:

  • Producing a small-scale batch of a drug candidate solely to supply a clinical trial.
  • Validating an analytical method (e.g., HPLC assay) needed to generate data for the core experiment.
  • Building a bespoke data-capture system that records results from the core experiment.
  • Cleaning and maintaining specialised equipment used exclusively in the core R&D project.

Because the distinction between core and supporting activities can be subtle, businesses often benefit from mapping activities early. The Eligibility Assessment & Risk Flags feature in GrantsMAX helps you identify which activities in your data may align with the program rules, but the final call rests with your accountant.

Pro tip: Document the “before” and “after” of an experiment. A one-line lab-book entry such as “tested compound X” will not satisfy substantiation. Instead, record the hypothesis you set out to test, the parameters you varied, and why the outcome was uncertain. This narrative will later feed your R&D project descriptions.

Step 2: Assess eligibility under the Australian R&D Tax Incentive rules

Eligibility is governed by the Income Tax Assessment Act 1997 and administered jointly by AusIndustry and the ATO. You need to pass two filters: AusIndustry’s registration of your R&D activities, and the ATO’s assessment of your R&D expenditure.

The “dominant purpose” test

For a core R&D activity to be registered, its dominant purpose must be to generate new knowledge. If the activity is already well understood in the relevant field, or if the outcome is routine optimisation rather than genuine experimentation, it may not qualify. For example:

  • Running a stability study on a product whose formulation is already well-characterised may not meet the test.
  • Tweaking growth media to increase yield by a minor percentage might be considered ordinary production improvement, not R&D, unless a significant technical risk is present.

AusIndustry and the Department of Industry, Science and Resources provide detailed guidance, and the ATO’s website publishes resources on how it views the dominant purpose rule. Always review the latest rulings for your industry.

Overseas-findings considerations

Biotech companies often collaborate with overseas CROs, access offshore biobanks, or run multi-site clinical trials. The R&D Tax Incentive generally requires that R&D activities be conducted in Australia, but a “limited overseas activities” exception exists. Broadly, an activity undertaken outside Australia may be eligible only if the entity has obtained an “overseas finding” from AusIndustry, which requires showing that:

  • The activity cannot be conducted in Australia because it requires facilities, expertise, or a site not available in Australia, or
  • Conducting the activity in Australia would be contrary to law, or
  • The activity is a clinical trial, a phase 0, I, II, or III trial of a therapeutic good, and the overseas finding is obtained for that trial.

The overseas finding must be sought before the end of the income year in which the activity is conducted. This is a procedural trap. Many biotechs miss the deadline and lose the ability to claim the offshore spend. As always, the ATO and AusIndustry provide the definitive rules; confirm the current application windows with them.

Warning: Never assume an overseas CRO contract automatically qualifies. You must hold a valid overseas finding. If your accountant flags uncertainty, pause and seek the finding before lodging.

The $20 million aggregated turnover threshold (and proposed change)

For companies with aggregated turnover under $20 million, the R&D tax offset is refundable, meaning if the offset exceeds your tax liability, you receive a cash refund. For companies above $20 million, the offset is non-refundable. The Australian Government has announced a reform, not yet enacted, to lift the refundable-offset turnover threshold from $20 million to $50 million, targeted for income years starting on or after 1 July 2026. This is a proposed change only; until the law passes, the existing threshold applies. GrantsMAX for growing companies helps track how such shifts may affect your claims, but always verify with a tax agent.

Step 3: Register with AusIndustry and understand the timeline

You must register your R&D activities with AusIndustry within 10 months after the end of your income year, usually by 30 April for a 30 June year-end. Registration is done through the online portal at business.gov.au. The registration covers the activities, not the dollars; you describe each R&D project and the core and supporting activities it encompasses. Registration does not, by itself, confirm eligibility; that is assessed later.

Pro tip: Treat the registration as a living document. As experiments evolve, update your descriptions. A sloppy registration can give the ATO a reason to question the claim. GrantsMAX drafts activity narratives from your data so your accountant can refine them, but you remain responsible for the factual accuracy.

After registration, you claim the R&D tax offset in your company tax return, attaching the AusIndustry registration number. The ATO reviews the claim alongside your return. Accountant Review & Lodge Workflow mirrors this sequence precisely: the pack is prepared, your accountant reviews it, and lodgment occurs only after sign-off.

Step 4: Gather and organise substantiation evidence

Substantiation is where many biotech claims falter. The ATO expects contemporaneous records that demonstrate both the activities and the expenditure. For biotech and life sciences, that means:

  • Laboratory notebooks (physical or electronic) with dated entries, signatures, and experimental results.
  • Project plans and design documents that set out the hypothesis and methodology.
  • Minutes of R&D steering meetings where decisions were made about experiments.
  • Timesheets showing hours spent on R&D activities, linked to specific projects.
  • Invoices and receipts for materials consumed, CRO fees, and subcontractor charges.
  • Contracts with external parties that clarify the scope of R&D work and whether the supplier was acting as an associate or an independent contractor.

For expenditures, the ATO requires that you can tie each dollar to an eligible R&D activity. Audit-Ready Evidence Trail indexes your emails, invoices, and timesheets so that every cost line in the claim maps to its source. Your accountant will view the trail during the review process.

Pro tip: Do not wait until tax time to assemble evidence. Set up a simple folder structure in your shared drive now, one folder per R&D project, with subfolders for lab records, contracts, and financials. Feed documents in weekly.

Step 5: Prepare the R&D Tax Incentive application pack

An effective application pack goes beyond the AusIndustry registration and the tax-return schedule. It should present a clear, believable story that aligns activities, costs, and evidence. The pack typically includes:

  1. Project narratives, a plain-English description of each R&D project, the experiments conducted, and the link to new knowledge.
  2. Activity and cost schedule, a detailed breakdown of eligible expenditure: salaries, contractor costs, consumables, and overheads attributable to R&D.
  3. Substantiation index, a table that maps each cost line to its supporting document.

For biotech, you will also want to capture the regulatory context. If a trial is conducted under a CTA or CTX, describe the phase and the scientific uncertainty being addressed. If GMP-grade material is produced for a trial, explain how the scale-up itself involved unresolved technical challenges (if it did).

AI Application Pack Drafting turns your business data into a draft pack, but the numbers and narratives must reflect your actual activities, your accountant will verify everything.

Warning: Never overreach. If a project contains elements that are commercial rather than experimental, clearly delineate them. Blurring the line can compromise the whole claim.

Step 6: Engage a registered tax agent to review, refine, and lodge

The R&D claim is lodged as part of your company tax return. Only a registered tax agent (or you, if you are willing to accept the risk) can prepare and lodge the return with the ATO. The agent’s role includes:

  • Reviewing the eligibility assessment and activity descriptions.
  • Checking the cost allocations against ATO guidance.
  • Ensuring the claim is consistent with the AusIndustry registration.
  • Lodging the return and handling any subsequent ATO queries.

GrantsMAX does not lodge, file, or guarantee outcomes. It prepares the evidence-backed pack so your accountant has complete, defensible material to work with. The full GrantsMAX workflow hands the pack to your accountant in a shared workspace, with all claim stages tracked from Draft to Review to Lodged. The business owns the claim at every stage.

Pro tip: Choose an accountant who actively works with R&D claims. Their familiarity with the ATO’s expectations and AusIndustry’s registration portal can save months of follow-up. GrantsMAX for accountants provides a white-label channel through which firms can manage multiple clients’ claims efficiently.

Step 7: Maintain records and prepare for the next annual claim cycle

The R&D Tax Incentive is an annual claim. Build a rhythm:

  • Each quarter, update your R&D activity records and reconcile costs.
  • Before year-end, conduct a draft eligibility review with your accountant.
  • Register with AusIndustry promptly after the income year ends.
  • Use the Annual Refresh feature to carry forward data and narratives, so you are not starting from scratch each year.

This disciplined cycle reduces errors and keeps your claim robust if the ATO ever reviews it.

Pro tips for biotech: handling overseas R&D and clinical trials

Overseas CROs and subcontractors

When you engage an overseas CRO, the expenditure may be eligible only if the R&D activities meet the overseas-finding criteria and you hold a valid finding. The cost of the CRO’s services is typically treated as expenditure on R&D activities conducted in Australia only to the extent the work is considered part of an Australian R&D project and falls within the allowed exception. Discuss the specific arrangement with your accountant early.

Phase I-III clinical trials

Clinical trials are a special case. Pharmaceutical and medical device companies running trials outside Australia can apply for an overseas finding for phases I, II, and III. The trial must be registered on a recognised clinical trials registry, and AusIndustry will expect documentation of the trial protocol and the unresolved scientific questions.

Common pitfalls

  • No laboratory notebooks, the ATO treats oral evidence as weak. Keep records.
  • R&D activity mixed with production, physically separate, if possible, and document the distinction.
  • Ignoring payroll records, salary claims need timesheets or a reasonable allocation method.

Why global R&D incentives matter for Australian biotech

While this article focuses on Australia, understanding the broader landscape can be useful. Many jurisdictions offer targeted R&D credits for life sciences. For example, the United States provides a federal research credit, with IRS Form 6765 detailing the claim process. New York State operates a Life Sciences Tax Credit Program, and New York City has a separate Biotechnology Tax Credit. The SBIR.gov resource describes the federal credit’s applicability to small innovative businesses. States collectively offer a patchwork of R&D tax credits, as surveyed by the National Governors Association. The U.S. Small Business Administration has a straightforward explainer for startups. Academic research, such as a ResearchGate review and an NBER working paper, analyses the economic effects of these incentives.

These programs highlight a global consensus that life sciences R&D should be encouraged. Australian biotech companies raising capital from US investors or partnering with US pharma companies often find it helpful to articulate how Australia’s R&D Tax Incentive compares. The structure, an offset rather than a deduction, can be a talking point. However, each program has its own rules, and what works in one country does not automatically translate. Always get local advice.

How the R&D Tax Incentive fits with other government grants

Australian biotech companies may also access the Export Market Development Grant (EMDG), state innovation grants, and sector-specific programs. The R&D Tax Incentive is not means-tested, so it can be claimed alongside grants, but the accounting treatment differs, grants are generally treated as assessable income, while the R&D offset reduces your tax liability or yields a cash refund. Your accountant will ensure the interactions are handled correctly. For businesses that export biotech products or services, GrantsMAX for founders and CFOs can help identify what you may be eligible for across the R&D Tax Incentive and EMDG. Grant & R&D Discovery and Matching scans opportunities and maps them to your data.

Looking ahead: proposed reforms and their potential impact

The announced (but not yet enacted) reform to raise the refundable-offset threshold from $20 million to $50 million would significantly change the calculus for many mid-sized biotechs. If passed, more companies would receive a cash refund, which could accelerate drug development cycles. Until then, the existing rules apply. Always verify the status of legislation with your accountant and with the ATO. GrantsMAX for growing companies tracks the shifting thresholds so that your claim remains current.

Summary: key takeaways

  1. Map activities carefully, distinguish core from supporting R&D and document the hypothesis-driven nature of your lab and trial work.
  2. Obtain overseas findings early, if you use offshore CROs or run clinical trials outside Australia, apply for the finding before the income year ends.
  3. Substantiation is not optional, contemporaneous records are your defence if the ATO reviews the claim.
  4. The accountant lodges, the business owns, the tax agent reviews and lodges the claim; GrantsMAX prepares the pack but does not lodge or guarantee outcomes.
  5. Stay current, thresholds and guidance evolve. Reassess eligibility each year with a qualified professional.

Biotech and life sciences R&D is complex, but a structured process makes the tax incentive accessible. If you want to reduce the manual burden and give your accountant a complete, evidence-backed pack, consider what GrantsMAX for R&D-active startups and technology companies can do for you.

Start preparing your next claim with clarity

Join the GrantsMAX waitlist today, and be among the first to use an AI agent that connects to your accounting data, discovers the R&D and grant opportunities you may be eligible for, and drafts the pack for your accountant to review and lodge. Visit grantsmax.com to sign up, no commitment, just a smarter way to prepare.